Hostname: page-component-745bb68f8f-g4j75 Total loading time: 0 Render date: 2025-01-12T18:38:46.306Z Has data issue: false hasContentIssue false
  • English
  • Français

Management of Health Care Workers Remotely Vaccinated for Hepatitis B Who Sustain Significant Blood and Body Fluid Exposures

Published online by Cambridge University Press:  21 June 2016

Michael B. Snyder
Michael B. Snyder*
Affiliation:
Division of Infectious Diseases and Hospital Epidemiology, Henry Ford Hospital, Detroit, Michigan
*
Division of Infectious Diseases and Hospital Epidemiology, Henry Ford Hospital, 2799 West Grand Boulevard, Detroit, MI 48202
Get access Rights & Permissions [Opens in a new window]

Extract

The availability of both plasma-derived and recombinant hepatitis B vaccines has given hospitals and other health care institutions the possibility of significantly reducing a major infectious hazard in the workplace. With the increasing use and acceptance of these vaccines, many employees who have a significant blood or body fluid exposure (percutaneous or mucous membrane) have already completed hepatitis B vaccination. Concerns have arisen over the duration of protection of vaccination, as it has been over five years since the introduction of the plasma-derived vaccine.

Type
Special Sections
Information
Infection Control & Hospital Epidemiology , Volume 9 , Issue 10 , October 1988 , pp. 462 - 464
Copyright
Copyright © The Society for Healthcare Epidemiology of America 1988

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Hadler, SC, Francis, DP, Maynard, JE, et al: Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med 1986; 315:209–214.CrossRefGoogle ScholarPubMed
2. Immunization Practices Advisory Committee: Update on hepatitis B prevention. MMWR 1987: 36:353–366.Google Scholar
3. Szmuness, W, Stevens, CE, Zang, , et al: A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax-B): A final report. Hepatology 1981; 1:377–385.CrossRefGoogle ScholarPubMed
4. Immunization Practices Advisory Committee: Recommendations for protection against viral hepatitis. MMWR 1985; 34:313–335.Google Scholar
5. Hollinger, FB: Features of viral hepatitis: Part I-Clinical features, in Fields, BN. et al (ed): Virology. New York, Raven Press, 1985. pp 1417–1433.Google Scholar
6. Horowitz, MM, Ershler, WB. McKinney, WP, et al: Duration of immunity after hepatitis B vaccination: Efficacy of low-dose booster vaccine. Ann Intern Med 1988; 108:185–189.CrossRefGoogle ScholarPubMed